ClinicalTrials.gg
CompletedNCT03306914Updated Jan 28, 2020

Comparing Human Albumin Versus Hydroxyethylstarch in Renal Transplant Recipients

An interventional study of Albumin resuscitation and Hydroxyethylstarch resuscitation in Anesthesia Morbidity, sponsored by Cairo University. Completed at 1 site in Egypt. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2020-01-28.

Sponsored by Cairo University · Not applicable, Interventional, and Supportive care

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
120
Allocation
Randomized
Ages
18 Years to 60 Years
Sex
All
01

Study summary

In this study we try to review the possible effects when using modern hydroxyethylstarch solutions 6 % versus albumin 5% during living donor renal transplantation.

02

Conditions studied

  • Anesthesia Morbidity
03

In context

Lead sponsor

Cairo University is the lead sponsor of 4,965 studies on the registry; 1,474 are open to participants now.

Of its 37 completed or terminated interventional studies of FDA-regulated products, 5 (14%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • end stage renal disease, for living donor renal transplantation

Exclusion criteria

Exclusion Criteria:

  • severe cardiac or hepatic dysfunction, re-transplantation, coagulopathy
05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
120 participants (actual)

Study arms

  • Active comparator
    Albumin group

    Albumin resuscitation Albumin 5%

    Other: Albumin resuscitation · Drug: Albumin 5%

  • Experimental
    Hydroxyethylstarch group

    Hydroxyethylstarch resuscitation Hydroxyethylstarch 6%

    Other: Hydroxyethylstarch resuscitation · Drug: Hydroxyethylstarch 6%

Interventions

  • OtherAlbumin resuscitation

    Albumin 5% is used as the intra-operative colloid

  • OtherHydroxyethylstarch resuscitation

    Hydroxyethyl starch 6% is used as the intra-operative colloid

  • DrugAlbuminsStudies of AlbuminsAlbumins pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Infusion of Albumin 5% intra-operatively

    Also known as: Albumin

  • DrugHydroxyethylstarch 6%

    Infusion of Hydroxyethylstarch 6% intra-operatively

    Also known as: Tetraspan

06

What researchers measure

Primary outcomes

  1. Occurrence of complications

    Increased creatinine and/or need for dialysis

    Time frame: 7 days

07

Study locations

1 site
  • Cairo University
    Cairo, Egypt
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 2017 to primary completion in Feb 2019, 15 months.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 6, 2017
First posted
Oct 11, 2017
StartActual
Oct 15, 2017
Primary completionActual
Feb 1, 2019
CompletionActual
Feb 1, 2019
Last update
Jan 28, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 28, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03306914
Lead sponsor
Cairo University
Responsible party
Ahmed Kareem (Principal Investigator, Cairo University) — Principal investigator
First posted
Oct 11, 2017
Start date
Oct 15, 2017
Primary completion
Feb 1, 2019
Completion
Feb 1, 2019
Last update
Jan 28, 2020

Study contacts

Ahmed Kareem
study director · Kasr Al-Ainy Hospiral, Cairo University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion